Naslov
Statins Usage in Croatia: The Effects of Introducing Generics

Autori
Vitezić, Dinko ; Matana Kaštelan, Zrinka ; Buble, Tonči ; Mršić-Pelčić, Jasenka ; Rosović, Vesna ; Kovačević, Miljenko ; Simonić, Ante

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the IXth World Conference on Clinical Pharmacology and Therapeutics ; u: Canadian Journal of Clinical Pharmacology 15 (2008) 3 / - , 2008, 740-741

Skup
World Conference on Clinical Pharmacology and Therapeutics (9 ; 2008)

Mjesto i datum
Quebec, Kanada, 27.07.2008. - 01.08.2008

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
statins; generics; usage; financial expenditure; national reimbursement list

Sažetak
The treatment of hypercholesterolemia with statins (or HMG-CoA reductase inhibitors) has an important place in the prevention of atherosclerosis. The aim of this study was to detect changes in statins usage and the effects of generic statins introduction on the national reimbursement list. Drug utilization and financial expenditure data were analyzed for statins prescribed by GPs. The data were obtained from the Croatian National Health Insurance Institute for the six-year period (2001-2006). Drug utilization data are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data are presented in Euros. In the period 2001-2006, the usage of statins increased 4.48 times (from 10.01 to 44.86 DDD/1000) while the related expenditure increased 3.16 times. The highest growth of 109.38% was in 2003 (in comparison to 2002) i.e. from 9.82 to 20.56 DDD/1000, and the related expenditure increased 1.8 times. The share of generic drugs increased from 1.01% to 45.38%. For the entire period simvastatin and atorvastatin remained not only the most frequently prescribed statins (ranging from 86.30% in 2001 to 95.97% in 2004), but also had the highest financial share (83.96% in 2001 to 90.27% in 2006). Share of generic simvastatin and atorvastatin increased from 1.17% to 49.64%. The usage of statins in Croatia increased considerably during the investigated period, especially in 2003 as a result of a legal change (the new Insurance Act) with the introduction of supplementary health insurance. The introduction of generic statins and restrictive measures on Croatian drug market slowed down the increase of financial expenditure.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA